Cystic fibrosis — adult pulmonary exacerbation
cf-pulmonary-exacerbation · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Acute worsening in an adult with cystic fibrosis - increased cough, sputum volume/purulence, breathlessness, reduced FEV1, weight loss, fatigue. Management is aggressive airway clearance and prolonged culture-directed IV antibiotics (typically targeting Pseudomonas) within specialist CF multidisciplinary care, alongside CFTR modulators and nutritional/comorbidity support.
Red flags
- Massive haemoptysis
- Pneumothorax (sudden pain/breathlessness)
- Severe hypoxaemia / respiratory failure
- Burkholderia cepacia complex or new resistant organism isolation
- Failure to recover FEV1 despite treatment
- Decompensated CF-related diabetes or severe weight loss
Assessment
Differential diagnosis
- Non-CF bronchiectasis exacerbation
- Allergic bronchopulmonary aspergillosis (common in CF)
- Non-tuberculous mycobacterial infection
- Pneumothorax (increased CF risk)
- Haemoptysis from bronchial vessels
- CF-related diabetes decompensation contributing
- Pulmonary embolism
Investigations
- Spirometry - fall in FEV1 from baseline is a key objective marker
- Sputum culture incl. Pseudomonas, Staph aureus (incl. MRSA), Burkholderia cepacia complex, and mycobacteria (AFB/NTM) with sensitivities
- CXR (compare baseline; exclude pneumothorax/consolidation); consider CT
- Oxygen saturation +/- ABG if severe
- FBC, U&E, LFTs, CRP, glucose/HbA1c (CF-related diabetes), weight/BMI
- Aspergillus serology/total IgE if ABPA suspected
- Review chronic colonisation history to target antibiotics
Management
- Manage within / in discussion with a specialist CF centre and MDT
- Intensify airway clearance physiotherapy and mucoactive therapy (dornase alfa, hypertonic saline)
- Start culture-directed antibiotics - usually TWO anti-pseudomonal agents of different classes IV for ~14 days to limit resistance
- Add anti-staphylococcal / organism-specific cover based on the patient's known flora (e.g. MRSA, Burkholderia)
- Optimise nutrition: high-calorie intake, pancreatic enzyme replacement, fat-soluble vitamins; manage CF-related diabetes
- Continue CFTR modulator therapy (e.g. elexacaftor-tezacaftor-ivacaftor) where eligible - it reduces exacerbations and improves lung function
- Treat complications: pneumothorax, massive haemoptysis (bronchial artery embolisation), ABPA
- Monitor renal function and drug levels with aminoglycosides; reassess FEV1 response
- Discharge planning with home IV/outpatient follow-up where appropriate
Drugs & doses
Anti-pseudomonal beta-lactam, e.g. ceftazidime 2 g IV TDS, or piperacillin-tazobactam 4.5 g IV TDS, or meropenem 2 g IV TDS - 14 days [verify local dose]
PLUS second anti-pseudomonal, e.g. tobramycin IV once daily (dose by level/weight) or ciprofloxacin - dual cover to limit resistance [verify dose/levels]
Anti-staphylococcal cover if S. aureus/MRSA colonised, e.g. flucloxacillin or vancomycin per sensitivities [verify dose]
Dornase alfa 2.5 mg nebulised once daily (mucolytic)
Nebulised hypertonic saline 7% BD (pre-treat with bronchodilator) [verify local dose]
Pancreatic enzyme replacement (e.g. pancreatin/CREON) with meals + fat-soluble vitamins (A,D,E,K)
CFTR modulator (e.g. elexacaftor-tezacaftor-ivacaftor) where genotype-eligible - continue through exacerbation [verify eligibility]
Disposition
Admit under / in close liaison with a specialist CF centre for IV antibiotics and MDT care (strict infection-control segregation). Selected patients: home/outpatient IV therapy. Lifelong specialist follow-up; transplant referral in advanced disease.
Complications & pitfalls
- Progressive bronchiectasis and chronic respiratory failure
- Pneumothorax, massive haemoptysis
- Multidrug-resistant and Burkholderia infection (prognostic and transplant implications)
- ABPA, NTM infection
- CF-related diabetes, malnutrition, osteoporosis
- Need for lung transplantation in end-stage disease
Exam pearls
- CF exacerbations are usually treated with TWO anti-pseudomonal antibiotics of different classes for ~14 days to maximise efficacy and limit resistance (CF Foundation / specialist consensus).
- Base antibiotic choice on the patient's own chronic sputum microbiology - CF patients carry individualised resistant flora.
- CFTR modulators (e.g. elexacaftor-tezacaftor-ivacaftor) have transformed outcomes and should be continued/optimised in eligible patients.
- Airway clearance and nutrition are as important as antibiotics - do not neglect physiotherapy, enzymes, and vitamins.
- Burkholderia cepacia complex isolation has major prognostic and transplant implications and needs strict infection control (patient segregation).
- Always manage via a specialist CF centre with MDT input.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.